Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
News about coronavirus in Florida and around the world is constantly emerging. It's hard to stay on top of it all but Health News Florida can help. Our responsibility is to keep you informed, and to help discern what’s important for your family as you make what could be life-saving decisions.

Moderna sues Pfizer over patents behind the COVID-19 vaccine

Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech, accusing the rivals of copying Moderna’s technology in order to make their own vaccine. Moderna said Friday, Aug. 26, 2022, that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed several years ago protecting the technology behind its preventive shot, Spikevax.
AP
Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech, accusing the rivals of copying Moderna’s technology in order to make their own vaccine. Moderna said Friday, Aug. 26, 2022, that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed several years ago protecting the technology behind its preventive shot, Spikevax.

Moderna CEO Stephane Bancel said in a prepared statement that the vaccine developer pioneered that technology and invested billions of dollars in creating it.

COVID-19 vaccine maker Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech, accusing the rivals of copying Moderna’s technology to make their own vaccine.

Moderna said Friday that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed several years ago protecting the technology behind its preventive shot, Spikevax.

The company filed patent infringement lawsuits in both U.S. federal court and a German court.

A Pfizer spokeswoman declined to comment, saying the company had not been served with a copy of the litigation.

Moderna and Pfizer’s two-shot vaccines both use mRNA technology to help patients fight the coronavirus.

Click here to read more of this article from NPR.